Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
This trial is a Phase II study. All patients are resectable Gastric or Gastroesophageal Junction Adenocarcinoma, Eastern Cooperative Oncology Group (ECOG) performance status 0-1.The purpose of this study is to evaluate the efficacy and safety of cadonilimab combined with chemotherapy with or without AK117 neoadjuvantin treatment of resectable Gastric or Gastroesophageal Junction Adenocarcinoma.
Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
DRUG: Cadonilimab|DRUG: AK117|DRUG: Oxaliplatin|DRUG: Tegafur-gimeracil-oteracil potassium|DRUG: Docetaxel|DRUG: 5-Fluorouracil
Incidence and severity of adverse events (AE), rate of surgical delays, abnormal laboratory findings of clinical significance, Up to approximately 2 years|Pathological complete response (pCR) rates, pCR is defined the 0% residual viable tumor cells in the primary tumor and sampled lymph nodes, Up to approximately 2 years
Major pathological response(MPR) rates, MPR is defined the â‰¤10% residual viable tumor cells in the primary tumor and sampled lymph nodes, Up to approximately 2 years|Tumor regression grade(TRG), Up to approximately 2 years|R0 resection rate, Up to approximately 2 years|Tumor descending stage rate, Proportion of subjects whose tumor TNM stage decreased from baseline before surgery, Up to approximately 2 years|ORR, Up to approximately 2 years|EFS, Up to approximately 2 years|OS, Up to approximately 2 years|PK, Serum drug concentrations of cadonilimab and/or AK117 in individual subjects at different time points, Up to approximately 2 years|ADA, Number of subjects with detectable anti-drug antibodies (ADA)., Up to approximately 2 years
This trial is a Phase II study. All patients are resectable Gastric or Gastroesophageal Junction Adenocarcinoma, Eastern Cooperative Oncology Group (ECOG) performance status 0-1.The purpose of this study is to evaluate the efficacy and safety of cadonilimab combined with chemotherapy with or without AK117 neoadjuvantin treatment of resectable Gastric or Gastroesophageal Junction Adenocarcinoma.